🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

14+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 14 recruiting trials for “parathyroid-carcinoma”

Phase 2RecruitingNCT06790706 ↗

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

🏥 Hospices Civils de Lyon📍 15 sites📅 Started Oct 2025View details ↗
NARecruitingNCT07068542 ↗

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

👨‍⚕️ Minghua Ge, Zhejiang Provincial People's Hospital📍 1 site📅 Started Jul 2025View details ↗
Phase 1RecruitingNCT06902376 ↗

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

👨‍⚕️ Siddharth Sheth, DO MPH, UNC Lineberger Comprehensive Cancer Center📍 2 sites📅 Started Jun 2025View details ↗
Phase 3RecruitingNCT06860971 ↗

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 35 sites📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06235216 ↗

Sacituzumab govitEcan in THYroid Cancers

👨‍⚕️ Alejandro García-Alvarez, M.D.; Ph.D., Hospital Universitario Vall d´Hebron📍 11 sites📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06440850 ↗

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

👨‍⚕️ Sasan Fazeli, City of Hope Medical Center📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06362694 ↗

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

🏥 Saint Petersburg State University, Russia📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06374602 ↗

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

🏥 Saint Petersburg State University, Russia📍 1 site📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06359847 ↗

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

👨‍⚕️ Yansong Lin, Ph D, Peking Union Medical College Hospital📍 1 site📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT06007924 ↗

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

👨‍⚕️ Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2023View details ↗
RecruitingNCT05994365 ↗

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 3 sites📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT06079333 ↗

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

👨‍⚕️ Ellen Kapiteijn, MD, PhD, Leiden University Medical Center📍 1 site📅 Started Jan 2023View details ↗
Phase 1RecruitingNCT03975231 ↗

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

👨‍⚕️ Sasan Fazeli, MD, City of Hope Medical Center📍 3 sites📅 Started Sep 2020View details ↗
RecruitingNCT03765333 ↗

GETNE Registration of Thyroid Cancer

👨‍⚕️ Jorge Hernando Cubero, M.D., Hospital Universitari Vall d'Hebron, Barcelona📍 1 site📅 Started May 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →